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Objectives: To evaluate health-related quality of life (HRQoL) in patients in different stages of chronic kidney
disease (CKD) up to initiation of dialysis treatment and to explore possible correlating and influencing factors.
Methods: Cross-sectional design with 535 patients in CKD stages 2–5 and 55 controls assessed for HRQoL through
SF-36 together with biomarkers.
Results: All HRQoL dimensions deteriorated significantly with CKD stages with the lowest scores in CKD 5. The
largest differences between the patient groups were seen in ‘physical functioning’, ‘role physical’, ‘general health’
and in physical summary scores (PCS). The smallest disparities were seen in mental health and pain. Patients in CKD
stages 2–3 showed significantly decreased HRQoL compared to matched controls, with differences of large
magnitude - effect size (ES)≥ .80 - in ‘general health’ and PCS. Patients in CDK 4 demonstrated deteriorated scores
with a large magnitude in ‘physical function’, ‘general health’ and PCS compared to the patients in CKD 2–3.
Patients in CKD 5 demonstrated deteriorated scores with a medium sized magnitude (ES 0.5 – 0.79) in ‘role
emotional’ and mental summary scores compared to the patients in CKD 4. Glomerular filtration rate <45 ml/min/
1.73 m², age≥ 61 years, cardiovascular disease (CVD), diabetes, C-reactive protein (CRP) ≥5 mg/L, haemoglobin
≤110 g/L, p-albumin≤ 35 g/L and overweight were associated with impaired HRQoL. CRP and CVD were the most
important predictors of impaired HRQoL, followed by reduced GFR and diabetes.
Conclusions: Having CKD implies impaired HRQoL, also in earlier stages of the disease. At the time for dialysis
initiation HRQoL is substantially deteriorated. Co-existing conditions, such as inflammation and cardiovascular
disease seem to be powerful predictors of impaired HRQoL in patients with CKD. Within routine renal care,
strategies to improve function and well-being considering the management of co-existing conditions like
inflammation and CVD need to be developed.
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When evaluating and improving health care in chronic
diseases, symptoms, function in daily life and well-being
are important patient outcomes [1]. Health-related qual-
ity of life (HRQoL) is a significant key indicator of how a
condition affects the patient’s life. HRQoL assessments
can therefore identify possible problem areas related to
health experiences. The concept of HRQoL builds on* Correspondence: agneta.pagels@ki.se
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reproduction in any medium, provided the orWHO’s definition of health [2] and has been defined as
the subjective assessment of the impact of disease and
its treatment across the physical, psychological and
social domains of functioning and well-being [3]. It is
characterized by being multidimensional (reflecting at
minimum physiological, psychological and sociological
aspects), temporal and subjective [2].
Chronic kidney disease (CKD) is defined as the pres-
ence of kidney damage or a glomerular filtration rate
(GFR)< 60 ml/min/1.73 m² for ≥ 3 months [4], with a
prevalence of approximately 10% of the adult population
[5]. Stages of CKD and levels of renal function areLtd This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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severe the renal insufficiency. Most CKD tend to
progress, and with declined kidney function multiple
disorders gradually develop, such as anemia, hyperten-
sion, inflammation (i.e. chronic activation of the immune
system), malnutrition metabolic and mineral-bone disor-
ders [6-8]. CKD 1–3 are not usually considered to
impact on the individual’s health experience, although
some disturbances may already have emerged. However,
in CKD 4 the individual perceives an increasing amount
of symptoms which may affect the HRQoL [7]. Fatigue,
muscle weakness, restless legs, cramps, itching, nausea
and loss of appetite [9-11] are frequently reported symp-
toms. Conditions like malnutrition, anemia, cognitive
dysfunction, sleep disorders, depression, reduced social
interaction, physical and sexual functioning and co-
morbidities like diabetes and cardiovascular disease
(CVD) also impair HRQoL in CKD patients [12-14].
Impaired HRQoL is well described among patients on
dialysis treatment [14,15]. Low HRQoL scores in dialysis
patients are further strong and independent predictors
of hospitalization and mortality [16-18]. However, some
studies have demonstrated deteriorated HRQoL also in
early stages of CKD, especially in physical health [19-21]
but also in mental health [22]. When following patients
in CKD 3–5 up to four years, it was shown that HRQoL
deteriorated over time, especially in those with a history
of congestive heart failure [20]. Impaired HRQoL have
also been shown shortly before (0–4 weeks) initiation of
dialysis treatment [23].
Few studies have examined HRQoL patterns in differ-
ent stages of CKD which indicate that more knowledge
is needed. The objective of this study was therefore to
evaluate HRQoL in patients with different stages of
CKD up to initiation of dialysis treatment and to explore
possible correlating and influencing factors. It was
assumed that HRQoL would decline progressively with
impaired renal function but also that co-morbidity, age,
gender, inflammation, anemia, hypertension and altered
nutritional markers would impact negatively on HRQoL.Table 1 Stages of chronic kidney disease (CKD) related to
levels of kidney function, i.e., glomerular filtration rate
(GFR) (National Kidney Foundation, 2002)
CKD stage Description GFR
(ml/min/1.73 m2)
1 Kidney damage with normal
or increased kidney function
≥ 90
2 Kidney damage with mildly
diminished kidney function
60 – 89
3 Moderately reduced kidney
function
30 – 59
4 Severely decreased kidney
function
15 – 29
5 Kidney failure < 15Materials and methods
Patients and study design
In this cross-sectional study 535 patients in CKD 2–5,
with a GFR ranging from 69 to 2 ml/min/1.73 m², and
55 controls from the Stockholm region in Sweden were
assessed for HRQoL through the SF-36 questionnaire
(see flow chart shown in Additional file 1: Table S1).
Register data from two prospective observational studies
(PROGRESS and PAUS) and the local Swedish Renal
Registry (SRR) were collected and merged according to
Additional file 1: Table S1. The participants in the PRO-
GRESS (‘Factors impacting progress of renal insuffi-
ciency’) cohort (n = 104) were recruited by convenience
at a renal outpatient clinic during 2002–2009. These
participants had a renal function corresponding to CKD
2–3 or 4–5. In the PAUS (‘Prospective study of renal re-
placement therapy in Stockholm’) cohort, 532 patients
were recruited consecutively from eight nephrology
units when initiating dialysis (SF-36 was collected at or
up to two weeks after first dialysis session) treatment
during 2000–2005. Of these, 330 patients from seven
units participated in the HRQoL survey. In this cohort,
97% of the participants had a renal function, corre-
sponding to CKD 5. From the local SRR cohort
(n = 468), 116 patients were recruited by convenience for
HRQoL assessments in connection to visits at a renal
outpatient clinic during 2004–2009. These participants
had a renal function corresponding to CKD 3–5. Con-
trols, matched for age, sex and living area to the CKD
2–3 patients were recruited. Of these, 31 were randomly
selected from the Swedish Register of the Total Popula-
tion and 24 recruited through the web site of the
regional university hospital. Inclusion criteria for the
controls were GFR ≥ 80 ml/min/1.73 m², absence of kid-
ney disease, cardiovascular disease (CVD), diabetes and




The 36-item short-form questionnaire (SF-36) [24] is a
self-administered general HRQoL questionnaire, not
specific to any disease or treatment group. The SF-36 is
covered by a conceptual model of HRQoL [25] and
includes 36 items that yield an 8- dimension profile on a
100-point scale, a higher score indicates a better per-
ceived health state. The eight dimensions are: Physical
function (PF), Role limitations caused by physical
problems (RP), Pain (BP), General health (GH), Vitality/
energy (VT), Social function (SF), Mental health/emo-
tional well-being (MH) and Role limitations caused by
emotional problems/mental health (RE). The items refer
to perceived health status during the last 4 weeks. The
PF, RP, BP and GH dimensions are usually summarized
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SF, MH and RE dimensions summarize to a mental com-
posite summary (MCS) [24,26]. The mean scores of the
Swedish reference population (n = 8930) aged 15–93 are:
PF = 87.9, RP = 83.2, BP = 74.8, GH= 75.8, VT= 68.8, SF =
88.6, RE = 85.7, MH=80.9, the mean summary scores
(n = 8004) are: PCS= 50 and MCS= 50 [27]. The SF-36
(version 1.0) was used as it covers relevant domains of
function and well-being, and most of the items in SF-36
are considered to have good sensitivity and responsive-
ness [28]. SF-36 has been used world-wide and been
recognized in various contexts and thus permits com-
parison within and between other conditions. It is valid
and reliable [27,29] and recommended by the National
Kidney Foundation guidelines [7].
Procedures and clinical measures
The patients from all three cohorts and the controls
were asked to complete the SF-36 by self-administration
in connection with their visits at the nephrology units.
Biomarkers for all participants (including the controls)
were blood test analyses, blood pressure, weight and
Body Mass Index (BMI). Blood test analyses were
haemoglobin (Hb), albumin, C-reactive protein (CRP),
phosphate, parathyroid hormone (PTH) and creatinine.
Moreover, GFR was determined in all participants. In
the controls and the patients in CKD 2–3 GFR was
examined by Iohexol-clearance, and in all other patients
GFR was estimated using the Modification of Diet in
Renal Disease (MDRD) formula [30,31]. Blood pressure
was measured in horizontal or sitting position and mean
arterial pressure (MAP) was calculated. Weight mea-
sures were performed and BMI was calculated.
Data analysis/statistical methods
IBMW SPSSW Statistics software (SPSS Inc., Chicago, IL,
USA 2006), version 15 and 20 were used for the statis-
tical analyses. Raw scores from the questionnaires were
transformed to scale scores using the software syntax for
SF-36 [27]. Data was analyzed and presented according
to outcome of normal distribution tests. Chi-square test
was used to analyze differences in nominal-level vari-
ables. Independent t-test was used to compare mean
HRQoL scores related to categorized correlates (gender,
history of co-morbidity, age, GFR, Hb, albumin, CRP,
blood pressure, BMI). Cut-off value for age was set at
the mean for the whole patient group, i.e. 61 years.
Other correlate cut-off values were set in accordance to
clinical guidelines, research findings and expertise know-
ledge, such as GFR at 45 ml/min/1.73 m², Hb-value at
110 g/L, CRP at 5 mg/L, albumin at 35 g/L, MAP at
110 mmHg and BMI at 20 and 30. Data from CKD 2
and 3 were pooled, as there were no significant differ-
ences in SF-36 scores between these groups. Differencesin HRQoL between CKD 2–3 and the matched controls
were evaluated by the Mann- Whitney U-test. HRQoL
differences between the three patient groups were ana-
lysed by the ANOVA one-way test. The magnitude of
differences in HRQoL scores was assessed using Cohen’s
d formula [32]. Cohen’s d is a standardized measure of
effect size (ES) and is computed as the difference be-
tween the mean scores of the compared groups divided
by the pooled within-group standard deviation (SD). The
Cohen’s d was computed, using the calculator elaborated
by Becker [33]. According to Cohen [32], benchmarks
for evaluating the importance of differences are: ES
values< 0.49 are considered as small, values of 0.50 –
0.79 as medium, and values≥ 0.80 are considered as
large. Predicting factors were computed through mul-
tiple linear regression analyses, using the enter method.
A random sample of 70 patients within CKD 5 (n = 394)
was extracted using a random number table.
The study was approved by the Regional Ethical Re-
view Board in Stockholm, Sweden.
Results
Demographic and biomarker characteristics are pre-
sented in Table 2, with the patients divided into three
groups according to their renal function; CDK 2–3, with
GFR range 69 – 31 ml/min/1.73 m² (n = 54), CKD 4,
with GFR range 29 – 15 ml/min/1.73 m² (n = 87) and
CKD 5, with GFR range 14 – 2 ml/min/1.73 m²
(n = 394) All biomarkers except BMI deteriorated signifi-
cantly (p = .000) across the CKD stages. CRP levels of
≥10 mg/L were significantly (p = .04) more frequent
among the men (40%) than the women (31%). CVD was
significantly more frequent in CKD 4–5 (53%) than in
CKD 2–3 (13%) (p = .000), and were also more frequent
among the men (56%) than the women (36%) (p = .000).
As shown in Table 3 and in Figures 1 and 2, the
HRQoL scores in all dimensions impaired progressively
and significantly (p = .000) across renal function levels
and CKD stages. The lowest scores were found in CKD
5. The largest differences between CKD stages were seen
in ‘physical function’, ‘role physical’, ‘general health’ and
PCS. The smallest disparities were seen in ‘pain’ and
‘mental health’. These smaller differences still met the
criteria for minimal clinically important difference
(MCID) of 3–5 score units [34]. Score differences found
between CKD 4 versus 5 in ‘general health’ and PCS did
not approach MCID. This was also observed in ‘mental
health’ and MCS between CKD 2–3 versus 4.
The patients in CKD 2–3 (GFR range 69–31 ml/min/
1.73 m²) had significantly lower scores on all HRQoL
dimensions than the matched controls (Table 3). ‘Gen-
eral health’ and PCS reached an ES of large magnitude
(1.28 and 0.85 respectively) between CKD 2–3 and
controls (Figure 3). ‘Role emotional’ and MCS both had
Table 2 Participants, grouping according to Chronic Kidney Disease (CKD) stages, renal diagnoses, co-morbidity,




















Age, M (SD) 61 (15) 47 (11.2) 62 (15.7) 62 (14.4) 48 (10.6)
Females, n (%) 175 (33) 22 (41) 35 (40) 118 (30) 22 (40)
BMI, Md (IQR) 25 (22–28) 25 (22–28) 25 (23–28) 25 (22–28) 24 (22–27)
MAP, M (SD) 101 (15.4) 96 (12.8) 94 (13.4) 103 (5.6) 88 (10.4)
GFR, ml/min/1.73 m²}, M (SD) 15 (16) 60 (6.6) 19 (3.1) 8 (3) 99 (12)
Hb, g/L, M (SD) 115 (17) 136 (14.2) 122 (12.6) 111 (15.6) 142 (11.5)
p-Albumin,g/L, M (SD) 34 (5.5) 38 (3.6) 36 (4.4) 33 (5.6) 40 (2.8)
p-Phosphate, mmol/L, M (SD) 1.8 (0.6) 1.1 (0.2) 1.4 (0.3) 2.0 (0.6) 1.1 (0.2)
PTH, ng/L, Md (IQR) 160 (76–303) 46 (35–56) 146 (91–204) 201 (103–345) 43 (38–53)
CRP, mg/L, Md (IQR) 5 (4–18) 2.4 (1–4.4) 4 (1.6–8.9) 6 (5–23) 0.89 (0.5–2.3)
CRP= 5–10 mg/L, n (%) 182 (34) 5 (9) 17 (20) 160 (41) 2 (4)
CRP = >10 mg/L, n (%) 163 (30) 4 (7) 13 (15) 146 (37) 3 (5)
n, (%)
Renal vascular disease 115 (22) 1 (2) 22 (25) 92 (23)
Primary glomerulonephritis 95 (18) 18 (33) 12 (13) 65 (17)
Familial, hereditary renal disease 58 (11) 12 (20) 6 (7) 40 (10)
Secondary glomerular systemic diseasesa 46 (9) 2 (4) 5 (6) 39 (10)
Other renal diagnose 101 (19) 13 (24) 20 (23) 68 (17)
CVD history b 264 (49) 7 (13) 49 (56) 208 (53)
Diabetes history c 158 (30) 11 (20) 40 (46) 107 (27)
Other co-morbidityd 119 (22) 2 (4) 22 (25) 95 (24)
* GFR=glomerular filtration rate in ml/min/1.73 m², examined by Iohexol-clearance.
** GFR estimated by MDRD.
BMI = Body Mass Index, MAP =Mean Arterial Pressure, Hb =Hemoglobin.
a Secondary glomerular systemic diseases except for diabetic nephropathy.
b Cardiovascular disease (CVD) includes cardiac infarction, congestive heart failure, stroke/TIA, atherosclerosis/peripheral vascular disease.
c Diabetic nephropathy or diabetes as co-morbidity.
dOther co-morbidity includes malignancy, chronic respiratory disease, chronic liver disease and rheumatic disease.
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had a medium sized ES (0.50–0.79).
The patients in CDK 4 demonstrated deteriorated
scores with a large magnitude in ‘physical function’ (ES =
1.05), ‘general health’ (ES = 0.94) and PCS (ES = 0.98)
compared to those in CKD 2–3 (Figure 3). ‘Role phys-
ical’ (ES = 0.70), ‘vitality’ (ES = 0.51) and ‘social function-
ing’ (ES = 0.64) showed differences of medium
magnitude.
The patients in CKD 5 demonstrated deteriorated
scores with a medium sized magnitude in ‘role emo-
tional’ (ES = 0.54) and MCS (ES = 0.52) compared to
those in CKD 4 (Figure 3). All other differences between
these groups had small ES.
Categorized correlates and HRQoL
Categorized correlates (GFR, age, gender, history of CVD,
diabetes, Hb, albumin, CRP, MAP, BMI) and PCS and MCS
scores are shown in Table 4. All significant differences(p< .05) met the required MCID for SF-36. Patients with
GFR< 45 ml/min/1.73 m² as well as CRP≥ 5 mg/L,
Hb≤110 g/L and albumin ≤35 g/L had significantly lower
scores on all HRQoL dimensions. Among those with CVD,
the PCS and all physical subscales were significantly lower
than in those with no history of CVD (p< .05). In those
with diabetes, PCS and ‘vitality’ were significantly lower
compared to those without diabetes. Patients with over-
weight (BMI> 30) had significantly lower scores on PCS,
‘physical function’ (p = .006) and pain (p= .041) than their
counterparts. However, no difference was seen between
patients with BMI≤20 compared to those with BMI >20.
The group aged ≥61 years showed lower scores on PCS,
‘physical function’ and ‘role physical’ than the younger
group, all at a significant level (p= .000). MCS was not
affected significantly by age, although the ‘role emotional’
subscale was impaired among those ≥61 years than in the
younger group (p= .004). Gender did not affect HRQoL sig-
nificantly, nor did hypertension (MAP> 110 mmHg).

























Physical Z =−3.53 100 83.7 (22) 57 (28.5) 49.2 (28.7) F = 67.1
functioning p= .000 (95–100) 77.7–89.7 50.9–63 46.3–52 p = .000
(PF) 94.2–99
Role Z =−3.08 100 69 (37.3) 39.9 (45) 22.1 (35.6) F = 64.3
physical p = .002 (100–100) 58.8–79.2 30.4–49.5 15.5–25.6 p = .000
(RP) 78.5–95.1
Bodily Z =−2.51 84 71.5 (27.2) 63.8 (30.3) 58.8 (31.4) F = 7.1
Pain p= .012 (74–100) 64.1–79 57.3–70.2 55.7–61.9 p = .008
(BP) 80.9–89.4
General Z =−5.63 85 59.4 (21.5) 40.8 (17.8) 40.2 (18.9) F = 49.3
health p= .000 (77–95) 53.5–65.3 37–44.6 38.3–42.1 p = .000
(GH) 78.9–86.8
Vitality, Z =−2.29 75 61.5 (25.1) 48.3 (26.1) 36.5 (23.9) F = 41.3
energy p= .022 (65–85) 54.6–68.3 42.8–53.9 34.2–38.9 p = .000
(VT) 68.2–77.8
Social Z =−2.39 100 83.3 (22.5) 67 (28.4) 57 (30.7) F = 33
functioning p= .017 (88–100) 77.2–89.5 60.9–73 53.9–60 p = .000
(SF) 90.3–96.9
Role Z =−2.59 100 79 (35.6) 62.1 (43.5) 38.8 (42.5) F = 34.3
emotional p = .009 (100–100) 69.3–88.7 52.8–71.3 34.6–43 p = .000
(RE) 86.6–98.9
Mental Z =−2.39 84 75.9 (18.2) 71.6 (18.7) 62.9 (23.1) F = 13
health p= .017 (80–92) 71–80.9 67.7–75.6 60.6–65.1 p = .000
(MH) 81.8–87.6
Physical Z =−4.35 55 45.8 (10.4) 34.9 (11.9) 32.9 (10.5) F = 66.6
Composite p = .000 (52.4–57.3) 43–48.6 32.4–37.4 31.9–33.9 p = .000
summary 51.4–55.1
(PCS)
Mental Z =−1.92 53 47.4 (10.6) 45 (12.4) 38.5 (12.8) F = 17.9
composite p = .055 (48.6–56) 44.5–50.3 42.4–47.6 37.2–39.7 p = .000
summary 49.3–53.5
(MCS)
* CKD-stage according to Table 1. GFR = glomerular filtration rate in ml/min/1.73 m².
# Post hoc Mann–Whitney U-Test.
## ANOVA One-way Test df = 533.
Confidence interval at 95% interval
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Multiple linear regression analyses were performed with
the response variable ‘PCS’ and ‘MCS’ respectively. Ten
explanatory variables were included: GFR, age, gender,
CVD, diabetes, Hb, log CRP, p-albumin, MAP and BMI.
When checking the assumptions (sample size, outliers,
multicolinearity, singularity, normality, linearity and
homoscedasticity), GFR was not normally distributed as
the majority of the patients belonged to CKD 5. A ran-
dom sample of 70 patients (with similar demographicdistribution) was therefore drawn from the CKD 5 group
and collapsed with CKD 2–4 data, creating a CKD 2–5
(n = 211) group.
A significant model for PCS emerged (F5,170 =31.062,
p = .000). The regression was a rather good fit; which
means that 46,2% of the variance in PCS was explained
by the model (Adjusted R square = .462). Five of the ten
explanatory variables had a significant predictive cap-
acity. Out of the model’s explanatory variables, ‘CRP’
(Beta =−.279, p = .000) and ‘CVD’ (Beta =−.233, p = 002)
Figure 3 Effect Sizes in HRQoL domains and summary scores
(M) in different stages of Chronic Kidney Disease (CKD) and in
controls. PF = Physical functioning, RP = Role physical, BP = Bodily
pain, GH=General health, VT = Vitality, SF = Social functioning,
RE = Role emotional, MH=Mental health, PCS = Physical summary
scores, MCS=Mental summary scores.
Figure 1 HRQoL domains and summary scores (M) in different
stages of Chronic Kidney Disease (CKD). PF = Physical functioning,
RP = Role physical, BP = Bodily pain, GH=General health, VT = Vitality,
SF = Social functioning, RE = Role emotional, MH=Mental health,
PCS = Physical summary scores, MCS=Mental summary scores.
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‘GFR’ (Beta = .191, p = .003), ‘diabetes’ (Beta =−.160,
p = .008) and ‘age’ (Beta =−.158, p = 021). The variables
gender, p-albumin, Hb, MAP and BMI showed no sig-
nificant predictive capacity. No significant model
emerged with MCS as response variable. In the final
model for MCS only one of the explanatory variables
demonstrated a significant predictive capacity: ‘CRP’
(Beta =−.271, p = .001). The regression was a poor fit;
only 11.7% of the variance in MCS was explained by the
model (Adjusted R square = .117, F5,170 =5.626, p = .000).
In summary, the results of the multiple regression ana-
lyses showed that CRP and CVD in the individual were
the most prominent predictors for impaired PCS among
adults with CKD 2–5, followed by GFR, diabetes and
age.
Discussion
Some limitations of the present evaluation ought to be con-
sidered. The patients were not randomly selected andFigure 2 Mean Physical Composite summary (PCS) and Mental
Composite Summay (MCS) scores related to declining levels of
kidney function/Glomerular Filtration Rate (GFR), ml/min/
1.73 m². GFR span <50> 30 not shown, since it was covered by
only one patient.neither were all of the controls, which could increase the
risk for bias. Moreover, the group sizes in different CKD
stages and GFR levels were disproportionate, with most
participants in CKD 5. This, as well as the context for this
study setting, has to be considered when interpreting the
results. However, the multiregression analyses were per-
formed with more proportional group sizes. Unfortunately,
the study did not cover patients in GFR levels between 31–
50 ml/min/1.73 m², but indicated that this GFR span may
embed a turning point for a pronounced drop in PCS
(Figure 2). Thus, our results confirm previous findings that
GFR values around 45 ml/min/1.73 m² seem to be a divid-
ing line for drop in HRQoL, especially in PCS [19]. Gender
distribution was somewhat skewed with a majority of
males, but this is in accordance with the gender distribution
in CKD. Furthermore, a cross-sectional design is limited by
only providing a snapshot and its difficulties to make causal
inference. Thus the evolution of the participants’ HRQoL
was not followed over time in this study, which may be of
importance when interpreting the illness trajectory. Follow-
up studies on HRQoL are still rare. Therefore, this should
be focused on in future research. When interpreting a
HRQoL instrument, one has to consider its limitations.
Ceiling and floor effects may skew the results. The indivi-
duals’ assessments of their health status are strongly sub-
jective and affected by surrounding factors like cultural
aspects and environmental changes, which should be taken
into account when interpreting and comparing results of
HRQoL [35]. Furthermore, the response shift phenomenon,
i.e. the patients’ adaption to or recalibration of their health
condition may have influenced the individual responses in
this study [36]. One can also presume that the patient’s
awareness of the diagnosis or ‘labeling’ phenomenon may
influence the individual’s health perception in asymptom-
atic conditions [13]. In this study solely biological variables
were collected for correlation analyses. This has to be kept
Table 4 Categorized correlates and HRQoL summary scores
PCS MCS
Parameter N Mean (SD) p-value Mean (SD) p-value
GFR <45 482 33.2 (10.7) .000 39.7 (13) .000
≥45 53 46.3 (10) 47.6 (10.6)
Age <61 281 37.6 (11.2) .000 39.8 (13.4) ns
≥61 254 31.1 (10.5) 41.1 (12.5)
Gender Male 360 34.6 (11.5) ns 40.4 (13) ns
Female 175 34.4 (11.1) 40.5 (12.8)
CVD Yes 264 29.6 (9.9) .000 39.4 (12.7) ns
No 271 39.4 (10.5) 41.4 (13.2)
Diabetes Yes 158 30.4 (10.8) .000 40.1 (13.1) ns
No 377 36.2 (11.2) 41.2 (12.6)
Hb ≤110 g/L 205 31.0 (10.2) .000 36.7 (12.9) .000
>110 g/L 330 36.7 (11.5) 42.8 (12.5)
p-Albumin ≤35 g/L 306 32.0 (10.8) .000 38.1 (12.9) .000
>35 g/L 227 37.9 (11.3) 43.6 (12.4)
CRP <5 mg/L 132 41.7 (11.2) .000 43.6 (12.4) .000
≥5 mg/L 345 31.9 (10.5) 38.7 (13.1)
MAP ≤110 mmHg 403 34.1 (11.7) ns 40.7 (12.9) ns
>110 mmHg 125 36.1 (10.1) 39.9 (12.8)
BMI ≤30 439 35.3 (11.4) .003 40.7 (12.8) ns
>30 76 31.2 (10.8) 41.1 (13.2)
BMI ≤20 55 36.6 (11.7) ns 40.6 (14.2) ns
>20 460 34.4 (11.3) 40.8 (12.7)
PCS = Physical Composite Summary, MCS =Mental Composite Summary, GFR = glomerular filtration rate in ml/min/1.73 m², CVD=Cardiovascular disease,
Hb =Hemoglobin CRP =C-Reactive Protein, MAP=Mean Arterial Pressure, BMI = Body Mass Index.
Significance level: p< .05
ns = not significant.
Pagels et al. Health and Quality of Life Outcomes 2012, 10:71 Page 7 of 11
http://www.hqlo.com/content/10/1/71in mind when drawing conclusions. If non-biological vari-
ables (such as psycho-social aspects, illness representations,
sense of coherence, locus of control, self-efficacy, coping
strategies and self-management) had been assessed, this
might have contributed to a more holistic perspective of
components correlating to and predicting HRQoL – espe-
cially the mental domains - in this patient group. Moreover,
one has to consider that the SF-36 does not capture all
dimensions that may be included in HRQoL for patients
with CKD, such as for example sleep, sexual and cognitive
functioning. Strengths of this study are the large number of
patients, especially in CKD 5, which has not been well stud-
ied previously regarding HRQoL. This study provides
insights into the changes in HRQoL throughout the CKD
illness trajectory, and contributes to providing more know-
ledge regarding HRQoL also in early CKD stages. The
study also highlights the relationship between HRQoL and
inflammation and CVD in this patient group.
In summary, the results showed that all HRQoL dimen-
sions deteriorated significantly across CKD stages, with the
lowest scores in CKD 5. The largest differences between
the patient groups were seen in ‘physical functioning’, ‘role
physical’, ‘general health’ and in PCS. The smallest disparitieswere seen in ‘mental health’ and ‘pain’. Patients in CKD
stages 2–3 showed significantly decreased HRQoL com-
pared to matched controls, with differences of large magni-
tude in ‘general health’ and PCS. Patients in CDK 4
demonstrated deteriorated scores with a large magnitude in
‘physical function’, ‘general health’ and PCS compared to
those in CKD 2–3. Patients in CKD 5 showed deteriorated
scores with a medium sized magnitude in ‘role emotional’
and MCS compared to those in CKD 4. GFR< 45 ml/min/
1.73 m², age≥ 61 years, CVD, diabetes, CRP≥5 mg/L,
Hb≤110 g/L, p-albumin≤ 35 g/L and overweight were all
associated to impaired HRQoL, indicating that HRQoL
related to renal function level, as well as to other conditions
associated to CKD, like inflammation and CVD. CRP and
CVD emerged as the most important predictors of
impaired HRQoL, followed by reduced GFR and diabetes.
Present results indicate that both PCS and MCS were
significantly impaired across CKD stages. As expected,
the lowest HRQoL scores were seen in the patients with
the most declined renal function, substantially deviating
from the Swedish reference population [27]. The decline
in HRQoL with deteriorating renal function is congruent
with previous findings [20]. The mean scores of the
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ating dialysis treatment) were lower than among those
in a Dutch study that assessed HRQoL 0–4 weeks prior
to dialysis initiation [23]. This confirms the continuous
deterioration of HRQoL with more advanced disease
stages. Compared with previous HRQoL assessments,
the current patients in CKD 5 showed even worse scores
than in several dialysis populations [37], suggesting that
this period of the disease trajectory may be exceptionally
vulnerable. The time period right before and at initiating
dialysis treatment can be described as a transitional
state, where the situation often appears as fragile and
uncertain to the patient. In addition to decline in phys-
ical health, stress, anxiety and depression often occur in
the period preceding dialysis initiation [38-40]. It is
therefore reasonable that also the mental dimensions
should be reflected in HRQoL assessed at this point.
The results show that CKD has a negative impact on
HRQoL – especially in the physical domains - already in
earlier stages of the disease. These results are in line
with findings in previous studies [19,20,22]. The patients
in CKD 2–3 (with GFR range 69–31 ml/min/1.73 m².)
scored significantly lower than the controls in all
HRQoL dimensions, with the largest differences shown
in ‘general health’ and PCS. The scores were also lower
compared to the Swedish reference population [27]. This
indicates that CKD even at an early stage seems to imply
restrictions in daily life, though it has been considered
not to impact the individual’s health experience. Little is
still known regarding illness perceptions and health
experiences in this patient group, why more research is
necessary on this topic.
The associations between GFR, CVD, diabetes,
decreased Hb- and p-albumin levels and impaired
HRQoL might be expected and are congruent with find-
ings in other studies [19,20]. However, the GFR level did
not – as assumed - show any prominent predictive cap-
acity in the multiple regression analyses. Interestingly,
this study instead demonstrates that inflammation and
CVD seem to be powerful predictors of impaired
HRQoL in patients with CKD. Moreover, the results in-
dicate that a relatively moderate increase in CRP may
affect HRQoL. These findings highlight that key ele-
ments concerning HRQoL in CKD patients are still not
settled and indicate that more attention should be paid
to partners like inflammation and CVD. To our know-
ledge, the relationship between inflammation and
HRQoL in this patient group is still not very well docu-
mented. It has previously been shown that increased
levels of inflammation related cytokines were associated
with deteriorated self-rated health [41]. Our results
showed elevated CRP levels across the CKD stages, with
increased occurrence of CRP> 5 mg/L with declined
kidney function (Table 2). This is in line with previousfindings [42,43] and the presumption of a chronic low-
grade inflammation process, starting already in early
stages of CKD [44]. Besides being an inflammation mar-
ker, CRP has also been pointed out as a strong predictor
of CVD events [45,46]. Moreover, and congruent with
previous research [47,48], about half of the patients had
a history of CVD, and about a third had diabetes
(Table 2). Conditions like inflammation, CVD and dia-
betes often appear in CKD patients, share risk factors
and affect the HRQoL. By screening for them at an early
stage the possibility for treatment and secondary preven-
tion of these factors increases and thereby also contri-
butes to improved well-being and function.
Research within renal care [19,20], in other conditions
like chronic heart failure [49] and also in the Swedish
reference population [27] have demonstrated women
reporting worse HRQoL than the men. However, no as-
sociation was found between HRQoL and gender in
current results. This finding was identified even though
a history of CVD and higher CRP-levels were more
common among males than in females.
The physical HRQoL domains showed large impair-
ments across the CKD stages in this study. The patients
in CKD 4 had impaired scores in ‘physical function’ ,
‘general health’ and PCS compared to the patients in
CKD 2–3. The decline in ‘vitality’ indicates that the dete-
riorated physical function might be connected to experi-
ences of lack of energy, feeling tired and worn out,
which are embraced in the ‘vitality’ concept. Fatigue/feel-
ing tired and lack of energy have emerged as the most
commonly reported symptoms in CKD 4–5 [50]. More-
over, it is well known that patients with advanced CKD
have reduced physical functioning and performance
[51,52] and that this is linked to experiencing fatigue
[10] and that inactivity has an impact on fatigue in
hemodialysis patients [53]. Our results confirm previous
findings that GFR around 45 ml/min/1.73 m² seem to be
a dividing line for drop in HRQoL, especially in PCS
[19]. It also supports the hypothesis of a turning point in
PCS at a relatively early and asymptomatic stage. This is
further confirmed by others who have found physical fit-
ness and functioning to be reduced already in earlier
CKD stages to approximately 70% of the expected norm
[51]. The loss of physical fitness and function demon-
strated in this and other studies is alarming and has to
be addressed already at a mildly diminished renal func-
tion. Enhanced physical activity and exercise training
programmes to patients with renal insufficiency have
been highlighted as interventions improving HRQoL
[12,51]. Furthermore, resistance training has been pro-
posed as a beneficial strategy also from an inflammation
perspective [45,54]. Other interventions to enhance
HRQoL in CKD patients, such as therapy optimization,
management of anemia, sleep disturbances, depression,
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have been suggested [12] as well as a comprehensive ap-
proach to a more patient-centered care [13]. From a
nursing perspective, retaining or increasing HRQoL and
well-being is a care goal [2] together with supporting
and empowering patients to achieve more of health liter-
acy, capability and autonomy. Interventions aiming at
giving feedback and discussing the HRQoL outcomes
face-to-face with the individual patient have been stud-
ied within oncology and diabetes care [55,56], and has
also been suggested as a future pathway within renal
care [57]. Especially in earlier stages of the disease these
discussions might make the patient aware of possible
growing decreases in function and well-being and may
help the patient to timely find healthy coping strategies.
Systematic implementation of monitoring and discussing
HRQoL would not only facilitate the communication
and improve the understanding of the patients’ perspec-
tive in a more holistic care approach, but also provide a
tool to screen for and prioritize problems. This could
then compose a base for supporting and improving the
patients’ self-efficacy [56] and psychosocial well-being
[55].
Implications for practice
Systematic assessments of HRQoL already from earlier
CKD stages could be a useful tool in renal care in order
to explore and improve perceived health and well-being.
The most affected HRQoL dimensions – perceptions of
general health and physical health components - insist
that recognition and management of them should be
attended. The impairments in mental health compo-
nents in CKD 5 stress the importance of psychosocial
support to patients about to commence dialysis treat-
ment. Also co-existing conditions and predictors like in-
flammation, CVD and also diabetes should be attended
when assessing HRQoL in CKD patients.
Implications for future research
These data suggest that HRQoL in CKD is not only
related to the renal function level, but also to other con-
ditions relating to CKD, like inflammation, CVD and
diabetes. However, longitudinal studies are needed to
confirm these findings. Follow-up studies on HRQoL
from earlier CKD stages with a comprehensive approach
are required, with a special interest in exploring altera-
tions within CKD stage 3. Little is still known regarding
illness perceptions and health experiences in this patient
group, why more research is necessary in this field.
There is also a need to further evaluate effective inter-
ventional strategies to enhance HRQoL in CKD patients,
including secondary prevention of risk factors and co-
existing conditions, educational and psychosocial
support and programmes for improved physical activity.Conclusion
Having CKD implies impaired HRQoL, also in earlier
stages of the disease. At the time for dialysis initiation
HRQoL is substantially deteriorated. Co-existing condi-
tions, such as inflammation and cardiovascular disease
seem to be powerful predictors of impaired HRQoL in
patients with CKD. Within routine renal care, strategies
to improve function and well-being considering the
management of co-existing conditions like inflammation
and CVD need to be developed.
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